Apixaban Impurity 169 | CAS 82570-64-7 - Request Quote
Apixaban Impurity 169
| SZ CAT No: | SZ-A062221 |
| CAS No | 82570-64-7 |
| Mol.F. | C14H14N2O2 |
| Mol.Wt. |
242.3 |
| Inv. Status |
Synthesis on demand |
Chemical Name :
Shipping Temperature :
HSN Code :
Country of Origin :
Smiles :
Usage Note:
Apixaban Impurity 169 is chemically (Z)-1,2-bis(4-methoxyphenyl)diazene. Apixaban Impurity 169 is supplied with detailed characterization data compliant with regulatory guideline. Apixaban Impurity 169 can be used for the analytical method development, method validation (AMV), Quality Controlled (QC) application for Abbreviated New Drug Application (ANDA) or during commercial production of Apixaban.
The product can be used as reference standards and further traceability against pharmacopeial standards (USP or EP) can be provided based on feasibility. SynZeal products are for analytical purpose only and not for human use.
Applications & Regulatory Use Cases
Buy 82570-64-7
Purchase 82570-64-7
Order 82570-64-7
Enquire 82570-64-7
price of 82570-64-7
82570-64-7 Supplier
82570-64-7 Manufacturer
82570-64-7 Exporter
buy high quality Apixaban Impurity 169
Purchase Apixaban Impurity 169
Apixaban Impurity 169 suppliers
Apixaban Impurity 169 manufacturers
Apixaban Impurity 169 price
Order Apixaban Impurity 169
Enquire Apixaban Impurity 169
Apixaban Impurity 169 cost
Apixaban Impurity 169 Supplier
Apixaban Impurity 169 Distributor
Apixaban Impurity 169 for Method Validation
Apixaban Reference Standard
Apixaban Impurity 169 for ANDA Filing
Apixaban Impurity 169 for Forced Degradation Studies
Apixaban Impurity 169 Identification Standards
Apixaban Impurity 169 for DMF Filing
Related Products
Disclaimer
SynZeal product information given on this website is as per the existing understanding while publishing the details on website. The customer is responsible for assessing the accuracy of the information at the time of actual purchase.
SynZeal will update these details as per new developments or findings in product specifications without further notice.